134
Participants
Start Date
November 30, 2011
Primary Completion Date
December 20, 2018
Study Completion Date
December 31, 2024
midodrine hydrochloride
Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
matching placebo
The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
Vanderbilt University, Nashville
University of Minnesota, Minneapolis
University of Calgary, Calgary
Alberta Health Services - Royal Alexandra Hospital, Edmonton
Royal Alexandra Hospital, Edmonton
Red Deer Regional Hospital, Red Deer
Victoria Cardiac Arrythmia Trials, Victoria
St. Boniface General Hospital, St. Boniface
New Brunswick Heart Centre, Saint John
Queen E II Health Sciences Centre, Halifax
Hamilton Health Sciences, Hamilton
University of Ottawa Heart Institute, Ottawa
Hopital Sacre Coeur de Montreal, Montreal
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke
Prairie Vascular Research Network/Regina General Hospital, Regina
Saskatoon Cardiology Consultants/Royal University Hospital, Saskatoon
Medical University of Lodz, Lodz
Vanderbilt University
OTHER
Dr. Bob Sheldon
OTHER